The investigation concerns Seres' statement on July 29, 2016 about its Phase 2 clinical study for ECOSPOR™, how it did not meet its primary endpoint of reducing the relative risk of Clostridium difficle infection recurrence. Following this announcement, Seres stock dropped. Two days before this announcement and drop in price, Seres' President, CEO and Chairman of the Board sold 20,000 shares of Seres at a much higher price.
If you are aware of any facts relating to this investigation, or purchased shares of Seres, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/mcrb or by contacting Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-seres-therapeutics-inc-mcrb-300307079.html
SOURCE Bronstein, Gewirtz & Grossman, LLC